B+
Bull case
25%
Probability
Target price
$11.00
+55.6% vs current
KYNB
Kyntra BioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$7.30
+3.3% vs current
B-
Bear case
25%
Probability
Target price
$4.50
-36.4% vs current
AI sentiment snapshot
Latest data as of 2026-07-22
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.8
Score
AI commentary
Company and SEC-reported materials are modestly constructive on pipeline progress, enrollment, and cash runway. However, social coverage is absent, headline activity is low, and post-release price reaction, analyst revisions, options skew, short interest, and employee sentiment are unavailable. The deterministic prior is positive, with expected returns of 1.13% over 5 days, 3.24% over 20 days, 5.18% over 60 days, and 6.80% over 120 days, but the evidence supports cautious monitoring rather than a high-conviction bullish view.
RankAlpha Sentiment Codex - 2026-07-22
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-20eventFG-3246 Phase 2 interim analysisHigh impact
The actively enrolling FG-3246 monotherapy trial in metastatic castration-resistant prostate cancer remains on track for an interim analysis in Q4 2026. Prior combination data reported median rPFS of 7.0 months overall and 10.1 months after one prior ARPI, but the monotherapy readout remains binary [#SEC-8K-2026-05-11] [#PR-EARNINGS-2026-05-12].
2026-10-20eventRoxadustat Phase 3 initiationHigh impact
Kyntra is finalizing the pivotal roxadustat Phase 3 protocol for lower-risk MDS following FDA feedback and anticipates trial initiation in the second half of 2026. Timing and partnership status remain uncertain [#SEC-8K-2026-05-11].
2027-07-22catalystCash runway supports executionHigh impact
Cash, cash equivalents, investments, and accounts receivable totaled $100.3 million as of March 31, 2026, with management indicating runway into 2028. This reduces near-term financing pressure but does not remove clinical or execution risk [#SEC-8K-2026-05-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology